Full Press Release Details
Immutep announces publication of TACTI-002 abstract
at ESMO s European Lung Cancer Congress 2022
24 March 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related
immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that new interim data from 2nd line NSCLC patients (Part B) of its phase II TACTI-002 trial has been published in an abstract
today in advance of ESMO s European Lung Cancer Congress (ELCC) 2022. ELCC 2022 will now be taking place in a virtual only format from 30 March 2022 to 2 April 2022.
| Title: | Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts | |
| Abstract: | Available at | |
| https://www.immutep.com/files/content/investor/presentation/2022/ELCC conference/ELCC 2022_TACTI-002 Part B_Abstract_Final.pdf |
The related poster presentation with new and updated data that are not part of the abstract will now be released by ELCC on
29 March 2022 at 12:00 noon, CEST and will subsequently be made available on Immutep s website at www.immutep.com.
About the TACTI-002 Trial
TACTI-002 (Two ACTive Immunotherapies) is being conducted in
collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada). The study is evaluating the combination of eftilagimod alpha (efti) with MSD s KEYTRUDA (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
The trial is a Phase II, Simon s two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in study centres across Australia, Europe, and the US.
Level 33, Australia Square
264 George Street, Sydney NSW 2000
Patients participate in one of the following:
TACTI-002 is an all-comer study in terms of PD-L1 status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC.
More information about the trial can be found on Immutep s website or on ClinicalTrials.gov (Identifier:
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep s current lead product
candidate is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for
autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep s large pharmaceutical partners.
Further information can be found on the Company s website www.immutep.com or by contacting:
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com
announcement was authorised for release by the CEO of Immutep Limited.
Level 33, Australia Square
264 George Street, Sydney NSW 2000